Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist
Choose a source to read (4)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
1 additional source qualifications - review before use
Adult major depressive disorder and generalized anxiety disorder; oral escitalopram tablets. Pediatric and oral-solution dosing are outside this summary.
Renal measure
CrCl in mL/min for the below-20 data boundary; no severe-renal dose algorithm.
Source revision
Label revision date not separately recorded; retrieval date is not the revision date.
Retrieved
2026-09-05 (not the revision date)
Labeled basic dosing
The adult starting/recommended dose is 10 mg orally once daily. Based on response and tolerability, increase no sooner than one week to a maximum 20 mg/day. Most older adults and patients with hepatic impairment use 10 mg/day.
Renal information and dialysis
No change is needed for mild or moderate renal impairment. At adult CrCl below 20 mL/min, a recommended dosage has not been determined. A dialysis-specific regimen is not supplied.
Selected warnings and limits
Monitor clinical worsening or suicidality, serotonin syndrome and hyponatremia; screen for bipolar disorder and review interacting medicines.
Source revision: Label revision date not separately recorded; retrieval date is not the revision date. | Retrieved: 2026-09-05. Retrieval date is not the revision date.
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Escitalopram tablets (adults) - selected U.S. labeling
Adult major depressive disorder and generalized anxiety disorder; oral escitalopram tablets. Pediatric and oral-solution dosing are outside this summary.
Renal method: CrCl in mL/min for the below-20 data boundary; no severe-renal dose algorithm. Retrieved: 2026-09-05
Renal Drug Handbook, fifth edition - Escitalopram tablets (adults)
Historical renal/RRT cross-check for the named ingredient; not a current U.S. prescribing instruction.
Renal method: Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods. Retrieved: 2026-09-05
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
Source scope / renal recommendation differences
Lexapro - product and source limitations
Use caution in severe impairment. The absence of a studied regimen is not evidence for a dialysis dose.
How to use this: Apply only to the stated formulation, indication and renal population.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Official source
Escitalopram tablets (adults) - selected U.S. labeling
Adult major depressive disorder and generalized anxiety disorder; oral escitalopram tablets. Pediatric and oral-solution dosing are outside this summary.
Method: CrCl in mL/min for the below-20 data boundary; no severe-renal dose algorithm.
Renal Drug Handbook, fifth edition - Escitalopram tablets (adults)
Historical renal/RRT cross-check for the named ingredient; not a current U.S. prescribing instruction.
Method: Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Adult major depressive disorder and generalized anxiety disorder; oral escitalopram tablets. Pediatric and oral-solution dosing are outside this summary.
RDM31-escitalopram-tablets-scope · Source section: Editorial scope tied to selected U.S. labelRenal section finder
Separate U.S. product-label layer
FDA / DailyMed dosing and renal information
Official
Escitalopram tablets (adults) - selected U.S. labeling
U.S. product labeling / DailyMed · Adult major depressive disorder and generalized anxiety disorder; oral escitalopram tablets. Pediatric and oral-solution dosing are outside this summary.
Renal method: CrCl in mL/min for the below-20 data boundary; no severe-renal dose algorithm. Source date: Label revision date not separately recorded; retrieval date is not the revision date. Retrieved: 2026-09-05
Selected dosing/renal sections read; concise local summary, not full prescribing information.
Labeled basic dosing
The adult starting/recommended dose is 10 mg orally once daily. Based on response and tolerability, increase no sooner than one week to a maximum 20 mg/day. Most older adults and patients with hepatic impairment use 10 mg/day.
No change is needed for mild or moderate renal impairment. At adult CrCl below 20 mL/min, a recommended dosage has not been determined. A dialysis-specific regimen is not supplied.
Mild or moderate impairment does not require adjustment. An adult dose has not been established for CrCl below 20 mL/min. Use caution in severe impairment. The absence of a studied regimen is not evidence for a dialysis dose.
Renal method: Use the renal measure explicitly present in the RX passage. Source date: Mirror revision not established in the reviewed passage. Retrieved: 2026-11-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
UK Renal Pharmacy Group / CRC Press · Historical renal/RRT cross-check for the named ingredient; not a current U.S. prescribing instruction.
Renal method: Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods. Source date: Fifth edition, 2019 Retrieved: 2026-09-05
Historical source, separately displayed. Renal tables were read with page-image inspection.
Historical renal and dialysis observations
The book retains usual dosing at 30-50 mL/min; at 10-30 and below 10, it favors low initiation and slow titration. HD/high-flux removal is described as absent, and peritoneal/continuous removal as unlikely.
RDM31-escitalopram-tablets-book · Source locator: Dose in renal impairment; renal replacement therapies; Other information
Source-specific limits
This is historical cautious-use advice where the label does not establish a dose below CrCl 20. The printed book bands overlap at 30; they are not an automated algorithm.
Source identity and provenance
Retrieved
2026-09-05
Handbook page
Printed page(s) 386-387; PDF page(s) 405,406
Renal-function method
Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.
Additional summaries stored on this page: 2 official-label, 1 RX List, 0 professional, 1 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.
